Report urges companies to hunt for more value from their patents
PatSnap’s “State of IP” report reveals intelligence about patent value, monetisation strategies, IP department budgets and more
PatSnap’s “State of IP” report reveals intelligence about patent value, monetisation strategies, IP department budgets and more
Brian Tenner sits down with IAM to discuss the company’s win and future strategy
GW’s recent ANDA lawsuit is a landmark moment, but will remain untypical of cannabis IP litigation
The recent rejection of a Mylan IPR petition – currently being challenged at the Federal Circuit – is good news for pharma patentees and bad news for generics
11 February 2021
Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary
04 February 2021
Two of country’s top industrials got successful results in the market that constitutes their number one business challenge
03 February 2021
South Korean PM’s comments show that IP enforcement does not happen in a vacuum
01 February 2021
Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system
21 January 2021
Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year
19 January 2021
While boosting transparency, the many difficulties faced by life sciences innovators when applying for protection in the country are not addressed
14 January 2021
As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.
22 December 2020
There is no clear stand-out in what is a highly interconnected industry. Instead a host of companies all rank as innovation leaders
18 December 2020
Failures to update IP management following the New Year could be costly for life sciences businesses
17 December 2020
Unlock unlimited access to all IAM content